Literature DB >> 27879478

Occurrence of HIV eradication for preexposure prophylaxis treatment with a deterministic HIV model.

Hyeygjeon Chang1, Claude Moog2, Alessandro Astolfi3.   

Abstract

The authors examine the human immunodeficiency virus (HIV) eradication in this study using a mathematical model and analyse the occurrence of virus eradication during the early stage of infection. To this end they use a deterministic HIV-infection model, modify it to describe the pharmacological dynamics of antiretroviral HIV drugs, and consider the clinical experimental results of preexposure prophylaxis HIV treatment. They also use numerical simulation to model the experimental scenario, thereby supporting the clinical results with a model-based explanation. The study results indicate that the protocol employed in the experiment can eradicate HIV in infected patients at the early stage of the infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27879478      PMCID: PMC8687162          DOI: 10.1049/iet-syb.2016.0008

Source DB:  PubMed          Journal:  IET Syst Biol        ISSN: 1751-8849            Impact factor:   1.615


  26 in total

1.  Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity.

Authors:  Yangxin Huang; Susan L Rosenkranz; Hulin Wu
Journal:  Math Biosci       Date:  2003-08       Impact factor: 2.144

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.

Authors:  Maame Efua S Sampah; Lin Shen; Benjamin L Jilek; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

4.  Pre-existence and emergence of drug resistance in HIV-1 infection.

Authors:  S Bonhoeffer; M A Nowak
Journal:  Proc Biol Sci       Date:  1997-05-22       Impact factor: 5.349

5.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Feng Fu; Martin A Nowak; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

Review 6.  The role of antigen-independent persistence of memory cytotoxic T lymphocytes.

Authors:  D Wodarz; R M May; M A Nowak
Journal:  Int Immunol       Date:  2000-04       Impact factor: 4.823

7.  Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Authors:  Manuel Battegay; Keikawus Arasteh; Andreas Plettenberg; Johannes R Bogner; Jean-Michel Livrozet; Mallory D Witt; Erik Mossdorf; Chan-Loi Yong; Wei Zhang; Sreeraj Macha; Frank Berger; Jerry Stern; Patrick Robinson; Anne-Marie Quinson
Journal:  Clin Ther       Date:  2011-08-27       Impact factor: 3.393

8.  Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV.

Authors:  H K Altes; D A Price; V A Jansen
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

Review 9.  A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance.

Authors:  R Colgrove; A Japour
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970

10.  HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.

Authors:  Rutao Luo; Michael J Piovoso; Javier Martinez-Picado; Ryan Zurakowski
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.